SEER INC
SEERNASDAQTrading Snapshot
- Day Range
- $1.92 – $2.08
- 52-Week Range
- $1.55 – $2.38
- Volume (shares)
- 105,717
- Avg Volume (shares)
- —
- Shares Outstanding
- 55.4M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- $16M
- Last Q Revenue
- $3M
- P/E Ratio
- -1.6
- P/S Ratio
- 8.0x
- EPS (TTM)
- $-1.23
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −6.1%
SEER INC
SEER
StockOtter · stockotter.spaceAbout SEER INC
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced updated follow-up analyses from a Phase 2 trial evaluating petosemtamab, an investigational IgG1-bispecif
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated inve
Seer to Report Third Quarter 2026 Financial Results on November 10, 2026
REDWOOD CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the thir
Seer and Nanyang Technological University to Present Early Findings from Landmark PRECISE-SG100K Proteomics Study at HUPO 2026
REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced that researchers from Nanyang Technological University will present early findings from the PRECISE-SG100K study at the 2
Seer Announces CFO Transition
REDWOOD CITY, Calif., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that David Horn, the Co
Seer Surpasses 100 Peer-Reviewed Customer Publications, Validating a New Era of Deep Proteomics at Scale
Six years after Seer's foundational Nature Communications paper, researchers across three continents have built a growing body of evidence demonstrating the power of deep, unbiased proteomics across genetics, aging, dise